Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00792571 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
A Phase 2 study, sponsored by Lung Biotechnology PBC.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00792571: Completed Phase 2 study, sponsored by Lung Biotechnology PBC.
NCT00792571 is a Phase 2 study that has completed, run by Lung Biotechnology PBC. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00792571, a Phase 2 study, has completed, sponsored by Lung Biotechnology PBC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.
Primary Outcome
A treatment-emergent adverse event (TEAEs) is defined as an event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments. AEs occurring more than 3 days after the last day study drug is taken in the study will not be included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only treatment-emergent adverse events occurrin
Interventions
- DRUG Beraprost Sodium Modified Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-02-28 |
| Est. Completion | 2013-11-30 |
| Phase | Phase 2 |
What the finished NCT00792571 record still lists
NCT00792571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Beraprost Sodium Modified Release is the first listed.
NCT00792571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00792571 about?
NCT00792571 is a clinical study titled "An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients". This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.
What is the current status of trial NCT00792571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2009-02-28. Estimated completion is 2013-11-30.
What interventions are being tested in trial NCT00792571?
The interventions under investigation include: Beraprost Sodium Modified Release (DRUG).
Who is sponsoring clinical trial NCT00792571?
This trial is sponsored by Lung Biotechnology PBC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00792571's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI